CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Rising incidence of infectious diseases worldwide
4.1.2. Growing demand for protein therapeutics
4.1.3. Increasing adoption of targeted immunotherapy
4.1.4. Rising number of fast track and orphan drug designations
4.1.5. U.S. FDA clearance of therapeutic monoclonal antibodies
4.2. Market Restraints & Challenges
4.2.1. High costs of primary antibodies
4.2.2. Cost constraints related to the adoption of membrane filters
4.3. Market Opportunities
4.3.1. Rising demand for protein therapeutics and growing risk of infectious diseases
4.3.2. Increase in R&D activities for the development of advanced antibodies
CHAPTER 5. GLOBAL ANTIBODY PRODUCTION MARKET – BY PROCESS
5.1. Upstream Processing
5.1.1. Bioreactors
5.1.1.1 Large-Scale Bioreactors
5.1.1.2 Single-Use Bioreactors (SUBS)
5.1.2. Consumables
5.1.2.1 Media
5.1.2.2 Reagents and Buffers
5.2. Downstream Processing
5.2.1. Chromatography Instruments
5.2.2. Chromatography Resins
5.2.2.1 Affinity Chromatography Resins
5.3. Ion Exchange (IEX) Chromatography Resins
5.4. Hydrophobic Interaction Chromatography (HIC) Resins
5.5. Multimodal Chromatography Resins
5.6. Filtration
5.6.1. Filtration Systems
5.6.2. Filtration Consumables and Accessories
CHAPTER 6. GLOBAL ANTIBODY PRODUCTION MARKET – BY ANTIBODY
TYPE
6.1. Polyclonal
6.2. Monoclonal
CHAPTER 7. GLOBAL ANTIBODY PRODUCTION MARKET – BY APPLICATION
7.1. Transplantation
7.2. Rheumatology
7.3. Cardiology
7.4. Gastroenterology
7.5. Infection
7.6. Oncology
CHAPTER 8. GLOBAL ANTIBODY PRODUCTION MARKET – BY END USER
8.1. Pharmaceutical and Biotechnology Companies
8.2. Diagnostic Laboratories
8.3. Research Institutes
CHAPTER 9. GLOBAL ANTIBODY PRODUCTION MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL ANTIBODY PRODUCTION MARKET - COMPANY
PROFILES
10.1. Sartorius AG
10.2. Danaher Corporation
10.3. Sigma-Aldrich Corporation
10.4. Eppendorf AG
10.5. Cellab GmbH
10.6. Integra Biosciences AG
10.7. Fibercell Systems Inc.
10.8. GE Healthcare
10.9. Merck KGAA
10.10. Thermo Fisher Scientific, Inc.
10.11. AbbVie, Inc.
10.12. Arsanis Biosciences GmbH
10.13. AbCellera Biologics, Inc.
10.14. Stem cell Technologies
10.15. Circadian Technologies Limited
CHAPTER 11. GLOBAL ANTIBODY PRODUCTION MARKET - COMPETITIVE
LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
